secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGM Biosciences, Inc. (—)
CIK:        0001496323
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055654
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net loss narrows to $49.8M; aplitabart colorectal trial enrollment exceeds target
--------------------------------------------------------------------------------

- Net loss $49.8M ($0.83/share) vs $59.3M ($1.33/share) in Q1 2023; operating expenses decreased.
- Cash and investments $293.8M at March 31, 2024, down from $337.7M at Dec 31, 2023.
- Aplitabart randomized colorectal trial enrollment exceeded target of 110 patients, now over 120; top-line PFS data expected by Q1 2025.
- Imvotamab completed first dose cohort in rheumatoid arthritis (6 active, 2 placebo); two higher-dose cohorts planned.
- FY 2024 guidance: GAAP OpEx $210-220M; collaboration rev ~$63M (mostly Q2); cash runway into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/0000950170-24-055654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/igms-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer